INVITROCUE

History

Year	Detail
2012	Invitrocue was founded in 2012 to commercialize proprietary 3D cell culture technology developed at A*STAR’s Institute of Bioengineering and Nanotechnology in Singapore, Massachusetts Institute of Technology Cambridge, and the Genome Institute of Singapore.
2016	The company partnered with ImageIQ, a software and contract research organization supporting preclinical research and clinical trials, to advance quantitative image analysis for preclinical researchers in Asia.
2016	The company partnered with SciKon, a US-based life sciences company, to focus its capability on fluidics devices.
2016	The company collaborated with the Genome Institute of Singapore for colorectal cancer organoids.
2017	The company collaborated with the Garvan Institute of Medical Research to provide further medical validation of Invitrocue’s technology for use in personalized real-time screening of cancer drugs.
2017	Invitrocue expanded its cell-based assaying business into skin and wound healing. The company signed a Master Services Agreement with Mundipharma Manufacturing Pte Ltd to develop in vitro skin and wound healing assays.
2019	The company signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, to cultivate and develop breast cancer models in the laboratory for Invitrocue’s proprietary Onco-PDO test.
2019	The company joint ventured with A*STAR scientist Dr. Chen Qingfeng to supply humanized immune system mice and cell products to research institutions, pharmaceutical, clinical research, and biotechnology companies.